We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biomarker-Based Blood Test Developed for Early Cancer Diagnosis

By LabMedica International staff writers
Posted on 20 Aug 2018
Print article
Image: A micrograph of the most common type of renal cell carcinoma (clear cell) on right of the image; non-tumor kidney is on the left of the image (Photo courtesy of Wikimedia Commons).
Image: A micrograph of the most common type of renal cell carcinoma (clear cell) on right of the image; non-tumor kidney is on the left of the image (Photo courtesy of Wikimedia Commons).
A blood test for early detection of kidney cancer is based on the KIM-1 (Kidney-injury-molecule-1) protein biomarker.

Renal cell carcinoma (RCC) has the potential for cure with surgery when diagnosed at an early stage. To this end, KIM-1 has been shown to be elevated in the plasma of RCC patients.

In the current study, investigators at Brigham and Women's Hospital (Boston, MA, USA) examined whether plasma KIM-1 could represent a means of detecting RCC prior to clinical diagnosis.

The investigators measured KIM-1 concentrations in samples from patients enrolled in the European Prospective Investigation into Cancer and nutrition (EPIC). KIM-1 levels from 190 participants who went on to develop RCC within the next five years were compared to those from 190 matched participants (same age, body mass index, smoking status, etc.) who remained healthy.

In samples with detectable levels of KIM-1, the average concentration was double in those who would develop kidney cancer. Furthermore, compared with a risk model including known risk factors of RCC (age, sex, country, body mass index, and tobacco smoking status), a risk model that additionally included KIM-1 substantially improved discrimination between cases and controls. In addition, high plasma KIM-1 concentrations were associated with poorer survival.

"Early detection of kidney cancer can be lifesaving. We can cure kidney cancer when we detect it at an early stage, but patients with advanced kidney cancer have a very high death rate," said contributing author Dr. Venkata Sabbisetti, a researcher in the renal division of Brigham and Women's Hospital. "However, kidney cancer is asymptomatic and many patients present with advanced kidney cancer at the time of diagnosis. Our results suggest that with further refinement, KIM-1 has the potential to identify patients with early, curable kidney cancer."

The KIM-1 study was published in the July 23, 2018, online edition of the journal Clinical Cancer Research.

Related Links:
Brigham and Women's Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.